American College of Toxicology

Life Edit Therapeutics Appoints Joy A. Cavagnaro to Its Scientific Advisory Board

Retrieved on: 
Wednesday, June 29, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Washington metropolitan area, FDA, University of North Carolina at Greensboro, Patient, LinkedIn, Engineering, Regulatory affairs, Edit, R, Society, SAB, Access, Center for Biologics Evaluation and Research, United States Air Force Scientific Advisory Board, Chapel Hill, Founder, Therapy, DABT, Gene editing, Drug discovery, RAC, RNA, Genome, Technology, Center, RAPS, SOT, University, Rgn, American College of Toxicology, Arnold, American College, Twitter, Duke University, Doctor of Philosophy, Pharmaceutical industry, Vaccine, FRAPS, Toxicology, Biochemistry, Research

Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).

Key Points: 
  • Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB).
  • We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics, said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio.
  • Joys expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases.
  • About Life Edit Therapeutics Inc.
    Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the worlds largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors.

Concarlo Expands Executive Leadership Team with the Appointment of Dr. Krishna Allamneni as Chief Development Officer

Retrieved on: 
Thursday, June 2, 2022
American College of Toxicology, Death, Time, Company, Research, Toxicity, TGA, MHRA, Partnership, American College, Society of Toxicology, Society, Hope, Therapy, Drug resistance, ANSM, FDA, CDK2, Health Canada, Patient, Jazz Pharmaceuticals, PMDA, Cancer, Medical device, Pharmaceutical industry, Toxicology

 BROOKLYN, N.Y., June 2, 2022 /PRNewswire/ -- Concarlo, a preclinical biotechnology company whose mission is to dramatically improve outcomes for patients with drug-resistant cancers by creating transformative therapies that control the p27 target, has appointed Dr. Krishna Allamneni as the Company's Chief Development Officer. Dr. Allamneni will lead Concarlo's internal pipeline development of therapeutics, and direct its strategy from target discovery to clinical trials and regulatory filings. As part of her role, she will also strategically manage and protect the company's IP assets.

Key Points: 
  • Dr. Allamneni will lead Concarlo's internal pipeline development of therapeutics, and direct its strategy from target discovery to clinical trials and regulatory filings.
  • Despite many important advances, drug resistance is one of the major reasons for the more than 600,000 deaths in America each year from cancer.
  • "Dr. Allamneni will play an instrumental role in Concarlo 's cutting-edge approach to clean up what precision oncology leaves behind," said Dr. Stacy Blain , Concarlo's Co-Founder, Chief Scientific Officer.
  • Dr. Allamneni has more than twenty years of R&D experience, including roles at Turning Point Therapeutics, Jazz Pharmaceuticals, and Roche/Genentech.